Preclinical and early clinical studies suggest that <i>CXCR4</i> blockade can impair tumor growth, limit metastatic spread, and enhance chemotherapy and immunotherapy efficacy, although hematopoietic side effects and infection risk necessitate careful therapeutic design. This evidence concerns the gene CXCR4 and infection.